Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
14 September 2022 - 06:31AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
AnPac Bio-Medical Science Co., Ltd. (the “Company”)
has received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market
LLC (“Nasdaq”) dated September 9, 2022, notifying the Company of the Staff’s determination to delist the Company’s
securities from The Nasdaq Capital Market because of the Company’s failure to regain compliance with the $1 per share bid price
requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1) (the “$1 Bid Rule”).
Pursuant to the Letter, unless the Company requests an appeal of the
Letter, trading of the Company’s American Depositary Shares will be suspended at the opening of business on September 20, 2022,
and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”) to remove the Company’s
securities from listing and registration on the Nasdaq Stock Market. The Company has the option to appeal the delisting determination
and intends to do so.
The Company intends to appeal the Staff’s determination to a
Hearings Panel (the “Panel”). Such a request will allow the Company’s American Depositary Shares to continue to be traded
(listed) pending the Panel’s decision.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. |
|
|
|
By: |
/s/ Dr. Chris Chang Yu |
|
|
Name: |
Dr. Chris Chang Yu |
|
|
Title: |
Co-Chairman of the Board of Directors and Co-Chief Executive Officer |
Dated: September 13, 2022
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Feb 2024 to Mar 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2023 to Mar 2024